GT201000088A - 2 -fluoro-2´desoxitetrahidrouridinas como inhibidores de citidina desaminasa - Google Patents

2 -fluoro-2´desoxitetrahidrouridinas como inhibidores de citidina desaminasa

Info

Publication number
GT201000088A
GT201000088A GT201000088A GT201000088A GT201000088A GT 201000088 A GT201000088 A GT 201000088A GT 201000088 A GT201000088 A GT 201000088A GT 201000088 A GT201000088 A GT 201000088A GT 201000088 A GT201000088 A GT 201000088A
Authority
GT
Guatemala
Prior art keywords
desoxitetrahydrouridins
desaminasa
citidine
fluoro
inhibitors
Prior art date
Application number
GT201000088A
Other languages
English (en)
Spanish (es)
Inventor
Gregory S Hamilton
Tsukamoto Takashi
Dana V Ferraris
Duvall Bridget
Lapidus Rena
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40251685&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201000088(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201000088A publication Critical patent/GT201000088A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GT201000088A 2007-10-16 2010-04-12 2 -fluoro-2´desoxitetrahidrouridinas como inhibidores de citidina desaminasa GT201000088A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98039707P 2007-10-16 2007-10-16

Publications (1)

Publication Number Publication Date
GT201000088A true GT201000088A (es) 2012-03-13

Family

ID=40251685

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201000088A GT201000088A (es) 2007-10-16 2010-04-12 2 -fluoro-2´desoxitetrahidrouridinas como inhibidores de citidina desaminasa

Country Status (39)

Country Link
US (4) US8268800B2 (OSRAM)
EP (2) EP2447272B1 (OSRAM)
JP (2) JP5496899B2 (OSRAM)
KR (1) KR101543049B1 (OSRAM)
CN (1) CN101827856B (OSRAM)
AT (1) ATE548374T1 (OSRAM)
BR (1) BRPI0818672B8 (OSRAM)
CA (1) CA2702274C (OSRAM)
CO (1) CO6270330A2 (OSRAM)
CR (1) CR11427A (OSRAM)
CY (3) CY1112781T1 (OSRAM)
DK (1) DK2207786T3 (OSRAM)
EA (1) EA018757B1 (OSRAM)
EC (1) ECSP10010095A (OSRAM)
ES (2) ES2384011T3 (OSRAM)
FI (2) FIC20230040I1 (OSRAM)
FR (2) FR23C1052I2 (OSRAM)
GT (1) GT201000088A (OSRAM)
HR (1) HRP20120419T1 (OSRAM)
HU (2) HUS2300044I1 (OSRAM)
IL (1) IL204732A (OSRAM)
JO (1) JO2778B1 (OSRAM)
LT (2) LTPA2023539I1 (OSRAM)
ME (1) ME00997B (OSRAM)
MX (1) MX2010004109A (OSRAM)
MY (1) MY147970A (OSRAM)
NI (1) NI201000055A (OSRAM)
NL (2) NL301256I2 (OSRAM)
NO (2) NO2023047I1 (OSRAM)
NZ (1) NZ584229A (OSRAM)
PL (1) PL2207786T3 (OSRAM)
PT (1) PT2207786E (OSRAM)
RS (1) RS52323B (OSRAM)
SA (1) SA08290661B1 (OSRAM)
SI (1) SI2207786T1 (OSRAM)
TW (1) TWI445539B (OSRAM)
UA (1) UA99476C2 (OSRAM)
WO (1) WO2009052287A1 (OSRAM)
ZA (1) ZA201002178B (OSRAM)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
EP2695609B1 (en) 2008-05-15 2019-12-11 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US20100055047A1 (en) * 2008-08-26 2010-03-04 Yiyu Zou Methods for treating bronchial premalignancy and lung cancer
KR20110104074A (ko) 2008-12-23 2011-09-21 파마셋 인코포레이티드 퓨린 뉴클레오시드의 합성
JO3262B1 (ar) 2009-04-06 2018-09-16 Otsuka Pharma Co Ltd توليفة من ديسيتابين مع مثبط سيتيدين دي أميناز واستخدامها في علاج السرطان
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
ES2628609T3 (es) * 2009-04-06 2017-08-03 Otsuka Pharmaceutical Co., Ltd. Combinación de fármacos antineoplásicos a base de citidina con inhibidor de citidina deaminasa y uso del mismo en el tratamiento de cáncer
CA2757743C (en) * 2009-04-06 2017-10-10 Eisai Inc. (2'-deoxy-ribofuranosyl)-1,3,4,7-tetrahydro-(1,3) diazepin-2-0ne derivatives for treating cancer
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
MX2012011171A (es) 2010-03-31 2013-02-01 Gilead Pharmasset Llc Fosforamidatos de nucleosido.
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
AP2014007575A0 (en) 2011-09-16 2012-04-30 Gilead Pharmasset Llc Methods for treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
SG11201506021XA (en) 2013-01-31 2015-08-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤
WO2015066162A1 (en) * 2013-10-29 2015-05-07 Otsuka Pharmaceutical Co., Ltd. Synthetic route to 2'-deoxy-2',2'-difluorotetrahydrouridines
EP3125920B1 (en) 2014-04-04 2020-12-23 Del Mar Pharmaceuticals Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer
PT3182996T (pt) 2014-08-22 2023-03-21 Celgene Corp Métodos de tratamento de mieloma múltiplo com compostos imunomoduladores em combinação com anticorpos
MX393043B (es) 2015-12-03 2025-03-24 Epidestiny Inc Composiciones que contienen decitabina, 5azacitidina y tetrahidrouridina y sus usos
WO2017158396A1 (en) * 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer
AU2019216531A1 (en) 2018-02-02 2020-09-24 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
JP2021535395A (ja) * 2018-08-28 2021-12-16 エッセンリックス コーポレーション アッセイ精度向上
US11224610B2 (en) * 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
KR102280330B1 (ko) * 2018-10-19 2021-07-21 인터올리고 주식회사 치료 효능을 개선한 핵산 변형체 및 이를 포함하는 항암용 약학 조성물
JP7433662B2 (ja) * 2018-10-19 2024-02-20 インターオリゴ・コーポレイション 治療効能を改善した核酸変形体及びそれを含む抗癌用薬学組成物
AU2020363412A1 (en) * 2019-10-08 2022-04-07 Taiho Pharmaceutical Co., Ltd. 2'-deoxy-2',2'-difluorotetrahydrouridines with high purity and methods of making the same
HUE069002T2 (hu) * 2020-02-25 2025-02-28 Otsuka Pharma Co Ltd Decitabint és cedazuridint tartalmazó szilárd orális adagolási formák
CN117835984A (zh) * 2021-03-26 2024-04-05 克利夫兰诊所基金会 使用胞苷脱氨酶抑制剂治疗rna病毒感染
WO2022254457A1 (en) * 2021-05-29 2022-12-08 Msn Laboratories Private Limited, R&D Center An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compounds
CA3236051A1 (en) 2021-10-19 2023-04-27 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
US20250127806A1 (en) * 2021-11-01 2025-04-24 St. John's University Injectable liquid pharmaceutical composition containing gemcitabine and a cytidine deaminase inhibitor
US20230271996A1 (en) * 2021-12-25 2023-08-31 Scinopharm Taiwan, Ltd. Process for preparing cedazuridine
EP4580635A1 (en) 2022-08-31 2025-07-09 Taiho Pharmaceutical Co., Ltd. Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017606A (en) * 1973-10-04 1977-04-12 The Upjohn Company Organic compounds and process
US4210638A (en) * 1978-03-17 1980-07-01 Pcr, Inc. Antiviral composition and method of treating virus diseases
US4275057A (en) 1980-01-28 1981-06-23 The United States Of America As Represented By The Department Of Health, Education And Welfare Seven-membered ring compounds as inhibitors of cytidine deaminase
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
JPS61500224A (ja) 1983-10-26 1986-02-06 グリ−ル、シエルダン　ビ− 腫瘍性組織を放射線に対して増感する医薬組成物
EP0184365B1 (en) 1984-12-04 1993-08-04 Eli Lilly And Company Improvements in the treatment of tumors in mammals
US4965374A (en) 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
EP0543976A4 (en) 1991-04-23 1993-11-10 Oglevee, Ltd. In vitro leaf petiole multiplication of pelargoniums
FR2682112B1 (fr) 1991-10-08 1993-12-10 Commissariat A Energie Atomique Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection.
US5426183A (en) 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5821357A (en) 1992-06-22 1998-10-13 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
US5371210A (en) 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5606048A (en) 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5594124A (en) 1992-06-22 1997-01-14 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
EP0641352B1 (en) 1993-02-23 1997-06-04 City Of Hope 4-ethoxy 5-fluoro 2'deoxyuridine
AU6081294A (en) 1993-05-14 1994-12-12 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB9311252D0 (en) * 1993-06-01 1993-07-21 Hafslund Nycomed As Cell growth regualtors
US5637688A (en) 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en) 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
AU5300396A (en) * 1995-03-01 1996-09-18 Human Gene Therapy Research Institute Radiation enhanced gene therapy for treatment of tumors
US6001994A (en) 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
US5760208A (en) 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
DK1156827T3 (da) * 1999-03-01 2007-02-05 Halogenetics Inc Anvendelse af sammensætninger omfattende CldC som strålingssensibilisatorer ved behandlingen af neoplastiske sygdomme
US6933287B1 (en) 1999-03-01 2005-08-23 Sheldon B. Greer Dramatic simplification of a method to treat neoplastic disease by radiation
CA2382222A1 (en) 1999-08-26 2001-03-01 Ted Vander Wiede Improvements relating to catheter positioning
US6462191B1 (en) 2000-07-13 2002-10-08 Air Products And Chemicals, Inc. Synthesis of 2-deoxy-2-fluoro-arabinose derivatives
JP3942414B2 (ja) 2000-11-29 2007-07-11 三井化学株式会社 Ｌ型核酸誘導体およびその合成法
DE60203260T2 (de) 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
AU2002257446A1 (en) 2001-05-18 2002-12-03 Rakesh Kumar Antiviral nucleosides
CA2454147C (en) * 2001-07-31 2013-05-21 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Inhibitor of dna methylation
BR0307712A (pt) 2002-02-14 2005-05-24 Pharmasset Ltd Composto, composição e uso dos mesmos no tratamento de infecções por flaviviridae e proliferação celular anormal
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
AU2003278904A1 (en) 2002-09-24 2004-04-19 Kornis Pharmaceuticals, Incorporated 1, 3, 5-triazines for treatment of viral diseases
US7265096B2 (en) 2002-11-04 2007-09-04 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
US8158770B2 (en) 2004-05-06 2012-04-17 University Of Rochester Content dependent inhibitors of cytidine deaminases and uses thereof
US20060014949A1 (en) 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
CN101076536A (zh) 2004-07-30 2007-11-21 药华医药股份有限公司 β－核苷的立体选择性合成
KR20070073958A (ko) 2004-12-08 2007-07-10 시코르, 인크. 디플루오로뉴클레오시드 및 이의 제조 방법
WO2008085611A2 (en) * 2006-11-27 2008-07-17 University Of Miami Designer theraphy of pancreatic tumors
WO2009021551A1 (en) 2007-08-13 2009-02-19 Universite De La Mediterranee A method for assessing the risk of toxicity in a chemotherapy
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
WO2010047698A1 (en) 2008-10-22 2010-04-29 University Of Alabama At Birmingham Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
ES2628609T3 (es) 2009-04-06 2017-08-03 Otsuka Pharmaceutical Co., Ltd. Combinación de fármacos antineoplásicos a base de citidina con inhibidor de citidina deaminasa y uso del mismo en el tratamiento de cáncer
JO3262B1 (ar) 2009-04-06 2018-09-16 Otsuka Pharma Co Ltd توليفة من ديسيتابين مع مثبط سيتيدين دي أميناز واستخدامها في علاج السرطان
CA2757743C (en) 2009-04-06 2017-10-10 Eisai Inc. (2'-deoxy-ribofuranosyl)-1,3,4,7-tetrahydro-(1,3) diazepin-2-0ne derivatives for treating cancer

Also Published As

Publication number Publication date
EP2207786A1 (en) 2010-07-21
TW200924786A (en) 2009-06-16
CY2023028I1 (el) 2024-02-16
UA99476C2 (en) 2012-08-27
NL301256I1 (OSRAM) 2024-01-03
NL301256I2 (nl) 2024-01-11
IL204732A (en) 2013-07-31
US8618075B2 (en) 2013-12-31
US20120289475A1 (en) 2012-11-15
NO2023047I1 (no) 2023-12-21
SA08290661B1 (ar) 2012-06-10
CY2023029I1 (el) 2024-02-16
CR11427A (es) 2010-08-16
DK2207786T3 (da) 2012-06-18
JO2778B1 (en) 2014-03-15
EA018757B1 (ru) 2013-10-30
NI201000055A (es) 2010-08-13
BRPI0818672B8 (pt) 2021-05-25
CN101827856A (zh) 2010-09-08
ATE548374T1 (de) 2012-03-15
HUS2300044I1 (hu) 2024-01-28
LTC2207786I2 (OSRAM) 2025-09-10
SI2207786T1 (sl) 2012-10-30
LTPA2023538I1 (OSRAM) 2024-02-26
JP2014177455A (ja) 2014-09-25
KR101543049B1 (ko) 2015-08-07
AU2008312435A1 (en) 2009-04-23
JP5496899B2 (ja) 2014-05-21
FR23C1051I2 (fr) 2025-02-07
CA2702274A1 (en) 2009-04-23
PL2207786T3 (pl) 2012-09-28
AU2008312435B2 (en) 2014-04-17
US8951987B2 (en) 2015-02-10
FIC20230039I1 (fi) 2023-12-22
FR23C1052I1 (fr) 2024-01-26
ME00997B (me) 2012-10-20
EP2447272B1 (en) 2017-02-01
FIC20230040I1 (fi) 2023-12-22
HUS2300045I1 (hu) 2024-01-28
JP5859588B2 (ja) 2016-02-10
NZ584229A (en) 2012-06-29
KR20100091978A (ko) 2010-08-19
US20150210730A1 (en) 2015-07-30
FR23C1052I2 (fr) 2025-02-07
PT2207786E (pt) 2012-05-28
LTPA2023539I1 (OSRAM) 2024-02-26
ECSP10010095A (es) 2010-07-30
MY147970A (en) 2013-02-28
WO2009052287A1 (en) 2009-04-23
ZA201002178B (en) 2011-05-25
CN101827856B (zh) 2013-02-06
IL204732A0 (en) 2010-11-30
US20140186335A1 (en) 2014-07-03
NL301257I2 (nl) 2025-11-06
CO6270330A2 (es) 2011-04-20
ES2384011T3 (es) 2012-06-28
CA2702274C (en) 2015-12-29
BRPI0818672B1 (pt) 2020-10-20
MX2010004109A (es) 2010-08-10
HK1146410A1 (en) 2011-06-03
AU2008312435A8 (en) 2014-07-24
FR23C1051I1 (fr) 2024-01-26
NO2023048I1 (en) 2023-12-21
RS52323B (sr) 2012-12-31
CY1112781T1 (el) 2016-02-10
US20090137521A1 (en) 2009-05-28
BRPI0818672A2 (pt) 2015-04-14
HRP20120419T1 (hr) 2012-07-31
US9567363B2 (en) 2017-02-14
JP2011500713A (ja) 2011-01-06
EP2207786B1 (en) 2012-03-07
EP2447272A1 (en) 2012-05-02
ES2616566T3 (es) 2017-06-13
EA201000642A1 (ru) 2010-10-29
TWI445539B (zh) 2014-07-21
US8268800B2 (en) 2012-09-18

Similar Documents

Publication Publication Date Title
GT201000088A (es) 2 -fluoro-2´desoxitetrahidrouridinas como inhibidores de citidina desaminasa
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
BR112012008385A2 (pt) inibidores de p13 cinase e uso dos mesmos.
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
ECSP099619A (es) Anticuerpos anti-robo4 y sus usos
HN2008000179A (es) Compuestos triciclicos,composiciones y procedimientos
CR20150088A (es) Anticuerpos anti-notch1 nrr
BR112013004341A2 (pt) composições pesticidas
CR11861A (es) Compuestos organicos
CO2018000668A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx/ca
CR20110497A (es) Nuevos anticuerpos anti-alfa5beta1 y sus usos
ECSP077316A (es) Compuestos imidazo-3-il-amina bicíclicos sustituidos
PA8792401A1 (es) Fenilendiaminas
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
ECSP12012218A (es) Derivados de piperidin-4-il azetidina como inhibidores de jak1
CO6450665A2 (es) Anticuerpos anti-fgfr3 y métodos que los utilizan
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
CR20150315A (es) Biocontrol de nemátodos fitoparásitos mediante paecilomyces
AR059096A1 (es) Anticuerpos anti- efrina -b2 y metodos que usan estos
ECSP088743A (es) Anticuerpos para egfl7 y métodos para su uso
EP2129672A4 (en) ESTER AND CARBAMATE AZAADAMANTANE DERIVATIVES AND METHODS OF USE
ECSP11011486A (es) Producción de hidrocarburos de isopreno mejorada que usa citanobacterias diseñadas geneticamente
BR112013000779A2 (pt) composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelial
BR112013000840A2 (pt) método para aumentar o efeito de forma ativada potencializada de anticorpo para molécula endógena biológica, composição farmacêutica e uso de combinação de molécula biológica endógena com forma ativada potencializada de anticorpo para a sintase no endotelial.